Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder

References

• GrunzeHKasperSGoodwinGBowdenCMollerHJThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatmentWorld J Biol Psychiatry2004512013515346536
   PubMed Web of Science ®Google Scholar
• HirschfeldRMAGuideline Watch: Practice Guideline for the Treatment of Patients with Bipolar Disorder2nd edArlington, VAAmerican Psychiatric Association2005
   Google Scholar
• BerkLHallamKTColomFEnhancing medication adherence in patients with bipolar disorderHum Psychopharmacol20102511620041478
   PubMed Web of Science ®Google Scholar
• PerlisRHOstacherMJMiklowitzDJClinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD studyJ Clin Psychiatry20107129630320331931
   PubMed Web of Science ®Google Scholar
• ScottJPopeMSelf-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalizationAm J Psychiatry20021591927192912411230
   PubMed Web of Science ®Google Scholar
• PopeMScottJDo clinicians understand why individuals stop taking lithiumJ Affect Disord20037428729112738048
   PubMed Web of Science ®Google Scholar
• SajatovicMDaviesMHroudaDREnhancement of treatment adherence among patients with bipolar disorderPsychiatr Serv20045526426915001726
   PubMed Web of Science ®Google Scholar
• VelliganDIWeidenPJSajatovicMThe expert consensus guideline series: adherence problems in patients with serious and persistent mental illnessJ Clin Psychiatry200970Suppl 414619686636
   PubMed Web of Science ®Google Scholar
• Gutierrez-RojasLJuradoDMartinez-OrtegaJMGurpeguiMPoor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sampleJ Affect Disord20101271–3778320576292
   PubMed Web of Science ®Google Scholar
• ScottJTacchiMJA pilot study of concordance therapy for individuals with bipolar disorders who are non-adherent with lithium prophylaxisBipolar Disord2002438639212519098
   PubMed Web of Science ®Google Scholar
• HaddadPMSharmaSGAdverse effects of atypical antipsychotics: differential risk and clinical implicationsCNS Drugs20072191193617927296
   PubMed Web of Science ®Google Scholar
• WilderCMElbogenEBMoserLLSwansonJWSwartzMSMedication preferences and adherence among individuals with severe mental illness and psychiatric advance directivesPsychiatr Serv20106138038520360277
   PubMed Web of Science ®Google Scholar
• SajatovicMJenkinsJHIs antipsychotic medication stigmatizing for people with mental illnessInt Rev Psychiatry20071910711217464788
   PubMed Web of Science ®Google Scholar
• JohnsonFROzdemirSManjunathRHauberABBurchSPThompsonTRFactors that affect adherence to bipolar disorder treatments: a stated-preference approachMed Care20074554555217515782
   PubMed Web of Science ®Google Scholar
• McIntyreRSUnderstanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global surveyJ Clin Psychiatry200970Suppl 351119570496
   PubMed Web of Science ®Google Scholar
• NewcomerJWHauptDWThe metabolic effects of antipsychotic medicationsCan J Psychiatry20065148049116933585
   PubMed Web of Science ®Google Scholar
• Saphris® (Asenapine) [Package insert]Kenilworth, NJSchering-Plough (Merck and Co, Inc)2011
   Google Scholar
• McIntyreRSCohenMZhaoJAlphsLMacekTAPanagidesJA 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed statesBipolar Disord20091167368619839993
   PubMed Web of Science ®Google Scholar
• McIntyreRSCohenMZhaoJAlphsLMacekTAPanagidesJAsenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trialJ Affect Disord2010122273820096936
   PubMed Web of Science ®Google Scholar
• CalabreseJStetLKotariHAsenapine as adjunctive treatment for bipolar mania: results of a placebo-controlled 12-week study and 40-week extension [abstract]Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22–26; New Orleans, LARed Hook, NYCurran Associates
   Google Scholar
• McIntyreRSCohenMZhaoJAlphsLMacekTAPanagidesJAsenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension studyJ Affect Disord201012635836520537396
   PubMed Web of Science ®Google Scholar
• McIntyreRSCohenMZhaoJAlphsLMacekTAPanagidesJAsenapine versus olanzapine in acute mania: a double-blind extension studyBipolar Disord20091181582619832806
   PubMed Web of Science ®Google Scholar
• YoungRCBiggsJTZieglerVEMeyerDAA rating scale for mania: reliability, validity and sensitivityBr J Psychiatry1978133429435728692
   PubMed Web of Science ®Google Scholar
• GuyWClinical global impressionsGuyWECDEU Assessment Manual for PsychopharmacologyWashington, DCUS Department of Health, Education and Welfare1976
   Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
   PubMed Web of Science ®Google Scholar
• TamayoJMMazzottiGTohenMOutcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidolJ Clin Psychopharmacol20072712613417414234
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesAdult Treatment Panel III (ATP III) of the National Cholesterol Education Program.01-33052001 National Institutes of Health.
   Google Scholar
• BrooksJOIIIGoldbergJFKetterTASafety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program For Bipolar DisorderJ Clin Psychiatry20117224024720868629
   PubMed Web of Science ®Google Scholar
• BaldwinDMayersASexual side effects of antidepressant and antipsychotic drugsAdv Psychiatr Treat20039202210
   Google Scholar
• [No authors listed.]Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorderMed Lett Drugs Ther201052920216523
   PubMed Web of Science ®Google Scholar
• PerlisRHBakerRWZarateCAJrOlanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trialJ Clin Psychiatry2006671747175317196055
   PubMed Web of Science ®Google Scholar
• VietaEBrugueEGoikoleaJMAcute and continuation risperidone monotherapy in maniaHum Psychopharmacol200419414514716711
   PubMed Web of Science ®Google Scholar
• BogartGTChavezBSafety and efficacy of quetiapine in bipolar depressionAnn Pharmacother2009431848185619809011
   PubMed Web of Science ®Google Scholar
• PotkinSGCohenMPanagidesJEfficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trialJ Clin Psychiatry2007681492150017960962
   PubMed Web of Science ®Google Scholar
• ShahidMWalkerGBZornSHWongEHAsenapine: a novel psychopharmacologic agent with a unique human receptor signatureJ Psychopharmacol200923657318308814
   PubMed Web of Science ®Google Scholar
• GlassmanAHSchizophrenia, antipsychotic drugs, and cardiovascular diseaseJ Clin Psychiatry200566Suppl 651016107178
   PubMed Web of Science ®Google Scholar
• DiefenbachGJWoolleySBGoetheJWThe association between self-reported anxiety symptoms and suicidalityJ Nerv Ment Dis2009197929719214043
   PubMed Web of Science ®Google Scholar
• DilsaverSCAkiskalHSAkiskalKKBenazziFDose-response relationship between number of comorbid anxiety disorders in adolescent bipolar/unipolar disorders, and psychosis, suicidality, substance abuse and familialityJ Affect Disord20069624925816904187
   PubMed Web of Science ®Google Scholar
• GhanbariREl MansariMShahidMBlierPElectrophysiological characterization of the effects of asenapine at 5-HT(1 A), 5-HT(2 A), alpha(2)-adrenergic and D(2) receptors in the rat brainEur Neuropsychopharmacol20091917718719116183
   PubMed Web of Science ®Google Scholar